摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N2-[(苄氧基)羰基]-N5-{[(2-甲基-2-丙基)氧基]羰基}鸟氨酸 | 98264-52-9

中文名称
N2-[(苄氧基)羰基]-N5-{[(2-甲基-2-丙基)氧基]羰基}鸟氨酸
中文别名
N-苄氧羰基-N'-叔丁氧羰基-D-鸟氨酸
英文名称
(R)-Nα-Z-Nδ-Boc-ornithine
英文别名
Z-D-Orn(Boc)-OH;Nα-Z-Nδ-Boc-D-ornithine;N2-[(benzyloxy)carbonyl]-N5-(tert-butoxycarbonyl)-D-ornithine;α-Cbz-γ-Boc-lysine;BOC-N-&-CBZ-D-ornithine;Z-D-Ornithine(Boc)-OH;(2R)-5-[(2-methylpropan-2-yl)oxycarbonylamino]-2-(phenylmethoxycarbonylamino)pentanoic acid
N2-[(苄氧基)羰基]-N5-{[(2-甲基-2-丙基)氧基]羰基}鸟氨酸化学式
CAS
98264-52-9
化学式
C18H26N2O6
mdl
——
分子量
366.414
InChiKey
RWQCKACYKKSOKK-CQSZACIVSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    98-99°C

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    26
  • 可旋转键数:
    11
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    114
  • 氢给体数:
    3
  • 氢受体数:
    6

安全信息

  • 海关编码:
    2924299090
  • 储存条件:
    2-8°C,干燥

SDS

SDS:65c95b9e22c6d74afa8b038946e5ca2d
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: Z-D-Orn(Boc)-OH
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: Z-D-Orn(Boc)-OH
CAS number: 98264-52-9

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C18H26N2O6
Molecular weight: 366.4

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    N2-[(苄氧基)羰基]-N5-{[(2-甲基-2-丙基)氧基]羰基}鸟氨酸N-甲基吗啉氯甲酸异丁酯 、 sodium tetrahydroborate 作用下, 以 乙二醇二甲醚 为溶剂, 反应 0.42h, 以91%的产率得到(R)-benzyl tert-butyl (5-hydroxypentane-1,4-diyl)dicarbamate
    参考文献:
    名称:
    BACTERIAL EFFLUX PUMP INHIBITORS
    摘要:
    本文揭示了以下式I的化合物及其盐。还披露了包含式I化合物的组合物以及使用式I化合物的方法。
    公开号:
    US20160271082A1
  • 作为产物:
    描述:
    二碳酸二叔丁酯 、 N2-苄氧羰基-D-鸟氨酸 在 sodium hydroxide 作用下, 以 四氢呋喃 为溶剂, 生成 N2-[(苄氧基)羰基]-N5-{[(2-甲基-2-丙基)氧基]羰基}鸟氨酸
    参考文献:
    名称:
    [EN] SULFONYLQUINOXALONE ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ ANTAGONISTS
    [FR] DERIVES D'ACETAMIDE SULFONYLQUINOXALONE ET COMPOSES ASSOCIES EN TANT QU'ANTAGONISTES DE LA BRADYKININE
    摘要:
    揭示了作为布雷金肽拮抗剂有用的磺酰基喹诺酮乙酰胺衍生物,可用于缓解与布雷金肽相关的症状,包括疼痛、炎症、支气管收缩、脑水肿等。
    公开号:
    WO2003093245A1
点击查看最新优质反应信息

文献信息

  • Iminolactones as tools for inversion of the absolute configuration of α-amino acids and as inhibitors of cancer cell proliferation
    作者:Christina Mernøe Jensen、Hsiao-Qing Chow、Ming Chen、Lin Zhai、Karla Frydenvang、Huizhen Liu、Henrik Franzyk、Søren Brøgger Christensen
    DOI:10.1016/j.ejmech.2016.02.037
    日期:2016.5
    give a diastereomeric ester mixture. Only iminolactones of l-amino acids were formed after cyclization of (1S,2S,5S)-2-hydroxypinan-3-one, and correspondingly only d-amino acid iminolactones were formed after reaction with (1R,2R,5R)-2-hydroxypinan-3-one. The protocol thus enables inversion of the absolute configuration of amino acids. Some members of the prepared library of iminolactones displayed significant
    通过将几种2-羟基酮与许多N-保护的d-和l -α-氨基酸酯化来制备亚氨基内酯文库。一些羟基酮是萜烯类来源的,而其他一些则是通过合成获得的。在中间体酯进行N-脱保护之后,游离胺自发地与酮缩合形成亚氨基内酯。将具有d-和l -α-氨基酸的(1S,2S,5S)-2-羟基pinan-3-one的酯部分聚合在α-碳原子上,得到非对映体酯混合物。(1S,2S,5S)-2-羟基pinan -3-one环化后仅形成1-氨基酸的亚氨基内酯与(1R,2R,5R)-2-羟基pinan -3-one反应后,形成d-氨基酸亚氨基内酯。因此,该方案能够反转氨基酸的绝对构型。制备的亚氨基内酯文库的某些成员对三种癌细胞系(EL4,MCF7,PC3)表现出显着的抗增殖作用,而对非恶性细胞系(McCoy,MCF10A,NIH3T3)的影响不明显。因此,亚氨基内酯似乎是制备选择性影响恶性细胞系增殖的药物的潜在先导结构。
  • [EN] DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY<br/>[FR] DERIVES DIPHENYLAZETIDINONE A ACTIVITE INHIBITRICE DE L'ABSORPTION DU CHOLESTEROL
    申请人:ASTRAZENECA AB
    公开号:WO2005061452A1
    公开(公告)日:2005-07-07
    Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.
    化合物的结构式(其中变量基团如定义所示)及其药学上可接受的盐、溶剂合物、该类盐的溶剂合物和它们的前药,以及它们作为治疗高脂血症的胆固醇吸收抑制剂的用途被描述。还描述了它们的制备方法和含有它们的药物组合物。
  • [EN] MITOCHONDRIA-TARGETING PEPTIDES<br/>[FR] PEPTIDES CIBLANT LES MITOCHONDRIES
    申请人:STEALTH BIOTHERAPEUTICS CORP
    公开号:WO2019118878A1
    公开(公告)日:2019-06-20
    Disclosed are non-natural peptides useful for the treatment and prevention of ischemia-reperfusion injury (e.g., cardiac ischemia-reperfusion injury) or myocardial infarction.
    披露了用于治疗和预防缺血再灌注损伤(例如心脏缺血再灌注损伤)或心肌梗死的非天然肽。
  • Potent Dibasic GPIIb/IIIa Antagonists with Reduced Prolongation of Bleeding Time:  Synthesis and Pharmacological Evaluation of 2-Oxopiperazine Derivatives
    作者:Shuji Kitamura、Hideto Fukushi、Toshio Miyawaki、Masaki Kawamura、Noriko Konishi、Zen-ichi Terashita、Takehiko Naka
    DOI:10.1021/jm0004345
    日期:2001.7.1
    2-oxopiperazine derivatives, possessing basic moieties at the 3- and the 4-positions, were synthesized and evaluated for their abilities to inhibit platelet aggregation and for their effects on bleeding time. Among the compounds, 2-[(3S)-4-[2-[(4-guanidinobenzoyl)amino]acetyl]-3-[3-[(4-guanidinobenzoyl)amino]propyl]-2-oxopiperazinyl]acetic acid (12c) showed a potent inhibitory effect on platelet aggregation and
    合成了一系列在3-位和4-位具有碱性部分的2-氧杂哌嗪衍生物,并对其抑制血小板聚集的能力及其对出血时间的影响进行了评估。在这些化合物中,2-[((3S)-4- [2-[(4-胍基苯甲酰基)氨基]乙酰基] -3- [3-[(4-胍基苯甲酰基)氨基]丙基] -2-氧代哌嗪基]乙酸(图12c)显示了对血小板聚集的有效抑制作用,以及功效和出血副作用之间的良好分离。静脉内以1.6 microg / mL / min的剂量注入化合物12c可完全防止豚鼠内皮损伤引起的动脉血栓形成。将出血时间延长至对照值的三倍的12c剂量为5.8 microg / mL / min。这些结果表明,化合物12c在血栓性疾病的临床治疗中可能有用,
  • Lipophilic oligopeptides with immunomodulating activity
    申请人:BioChem Pharma Inc.
    公开号:US05688771A1
    公开(公告)日:1997-11-18
    New, small and structurally simple immunomodulating oligopeptides are disclosed. The oligopeptides of this invention possess a long, lipophilic alkyl chain. These immunomodulating oligopeptides can be used in conjunction with anti-viral or anti-cancer agents in the treatment of human and animal diseases. Processes for the syntheses of immunomodulating chemicals are also disclosed.
    本发明揭示了新型的、小型的、结构简单的免疫调节寡肽。该发明的寡肽具有长的、亲脂性的烷基链。这些免疫调节寡肽可以与抗病毒或抗癌药物一起用于治疗人类和动物疾病。本发明还揭示了合成免疫调节化学物质的方法。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐